BOXED O
WARNING O
: O
WARNING O
: O
EMBRYO-FETAL O
TOXICITY O
AND O
VENOUS O
THROMBOEMBOLISM O
EMBRYO B-OSE_Labeled_AE
- I-OSE_Labeled_AE
FETAL I-OSE_Labeled_AE
TOXICITY I-OSE_Labeled_AE
If O
thalidomide O
is O
taken O
during O
pregnancy B-Not_AE_Candidate
, O
it O
can O
cause O
severe O
birth B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
or O
embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
fetal I-OSE_Labeled_AE
death I-OSE_Labeled_AE
. O

Thalidomide O
should O
never O
be O
used O
by O
females O
who O
are O
pregnant B-Not_AE_Candidate
or O
who O
could O
become O
pregnant B-NonOSE_AE
while O
taking O
the O
drug O
. O

Even O
a O
single O
dose O
[ O
1 O
capsule O
( O
regardless O
of O
strength O
) O
] O
taken O
by O
a O
pregnant B-Not_AE_Candidate
woman O
during O
her O
pregnancy B-Not_AE_Candidate
can O
cause O
severe O
birth B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
. O

Because O
of O
this O
toxicity O
and O
in O
an O
effort O
to O
make O
the O
chance O
of O
embryo B-NonOSE_AE
- I-NonOSE_AE
fetal I-NonOSE_AE
exposure I-NonOSE_AE
to I-NonOSE_AE
THALOMID I-NonOSE_AE
( O
r O
) O
( O
thalidomide O
) O
as O
negligible O
as O
possible O
, O
THALOMID O
( O
r O
) O
( O
thalidomide O
) O
is O
approved O
for O
marketing O
only O
through O
a O
special O
restricted O
distribution O
program O
: O
THALOMID O
REMS O
( O
r O
) O
program O
, O
approved O
by O
the O
Food O
and O
Drug O
Administration O
. O

You O
can O
get O
the O
information O
about O
THALOMID O
and O
the O
THALOMID O
REMS O
program O
on O
the O
Internet O
at O
www.celgeneriskmanagement.com O
or O
by O
calling O
the O
manufacturer O
's O
toll-free O
number O
1-888-423-5436 O
. O

VENOUS O
THROMBOEMBOLISM O
The O
use O
of O
THALOMID O
( O
r O
) O
( O
thalidomide O
) O
in O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
results O
in O
an O
increased O
risk O
of O
venous B-OSE_Labeled_AE
thromboembolism I-OSE_Labeled_AE
, O
such O
as O
deep B-OSE_Labeled_AE
venous I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
. O

This O
risk O
increases O
significantly O
when O
thalidomide O
is O
used O
in O
combination O
with O
standard O
chemotherapeutic O
agents O
including O
dexamethasone O
. O

In O
one O
controlled O
trial O
, O
the O
rate O
of O
venous B-OSE_Labeled_AE
thromboembolism I-OSE_Labeled_AE
was O
22.5 O
% O
in O
patients O
receiving O
thalidomide O
in O
combination O
with O
dexamethasone O
compared O
to O
4.9 O
% O
in O
patients O
receiving O
dexamethasone O
alone O
( O
p O
= O
0.002 O
) O
. O

Patients O
and O
physicians O
are O
advised O
to O
be O
observant O
for O
the O
signs O
and O
symptoms O
of O
thromboembolism B-NonOSE_AE
. O

Instruct O
patients O
to O
seek O
medical O
care O
if O
they O
develop O
symptoms O
such O
as O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
, O
chest B-NonOSE_AE
pain I-NonOSE_AE
, O
or O
arm B-NonOSE_AE
or O
leg O
swelling I-NonOSE_AE
. O

Consider O
thromboprophylaxis O
based O
on O
an O
assessment O
of O
individual O
patients O
' O
underlying O
risk O
factors O
. O

EXCERPT O
: O
WARNING O
: O
EMBRYO-FETAL O
TOXICITY O
AND O
VENOUS O
THROMBOEMBOLISM O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

EMBRYO-FETAL O
TOXICITY O
* O
If O
thalidomide O
is O
taken O
during O
pregnancy O
, O
it O
can O
cause O
severe O
birth O
defects O
or O
embryo-fetal O
death O
. O

Thalidomide O
should O
never O
be O
used O
by O
females O
who O
are O
pregnant O
or O
who O
could O
be O
pregnant O
while O
taking O
the O
drug O
. O

Even O
a O
single O
dose O
[ O
1 O
capsule O
( O
regardless O
of O
strength O
) O
] O
taken O
by O
a O
pregnant O
woman O
during O
her O
pregnancy O
can O
cause O
severe O
birth O
defects O
. O

* O
Pregnancy O
must O
be O
excluded O
before O
start O
of O
treatment O
. O

Prevent O
pregnancy O
thereafter O
by O
the O
use O
of O
two O
reliable O
methods O
of O
contraception O
. O

( O
5.1 O
, O
8.3 O
) O
THALOMID O
( O
r O
) O
( O
thalidomide O
) O
is O
only O
available O
through O
a O
restricted O
distribution O
program O
, O
the O
THALOMID O
REMS O
( O
r O
) O
program O
( O
5.2 O
) O
. O

VENOUS O
THROMBOEMBOLISM O
* O
Significant O
increased O
risk O
of O
deep O
vein O
thrombosis O
( O
DVT O
) O
and O
pulmonary O
embolism O
( O
PE O
) O
in O
patients O
with O
multiple O
myeloma O
receiving O
THALOMID O
( O
r O
) O
( O
thalidomide O
) O
with O
dexamethasone O
( O
5.3 O
) O
. O

